drugset
drugset / Trial / NCT02467608

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

NCT02467608 ↗

Phase 2/3 Completed 557 enrolled Orient Pharma Co., Ltd. National Defense Medical Center, Taiwan · collabNational Research Program for Biopharmaceuticals, Taiwan · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis

Timeline

Start
2012-12-06
Primary completion
2019-01-09
Completion
2019-01-09

Drugs

EvaluationDrugModalityDoseRoute
Background Ethambutol Small molecule 800 mg Oral
Background Ethambutol Small molecule 1600 mg Oral
Background Isoniazid Small molecule 300 mg Oral
Background Isoniazid Small molecule 600 mg Oral
Background Pyrazinamide Small molecule 1000 mg Oral
Background Pyrazinamide Small molecule 2000 mg Oral
Background Rifampin Small molecule 450 mg Oral
Background Rifampin Small molecule 600 mg Oral

Indications

pulmonary tuberculosis